Howard Yeh

2.5k total citations · 1 hit paper
24 papers, 1.7k citations indexed

About

Howard Yeh is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Howard Yeh has authored 24 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 10 papers in Molecular Biology and 10 papers in Oncology. Recurrent topics in Howard Yeh's work include Multiple Myeloma Research and Treatments (13 papers), Bone health and treatments (7 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). Howard Yeh is often cited by papers focused on Multiple Myeloma Research and Treatments (13 papers), Bone health and treatments (7 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). Howard Yeh collaborates with scholars based in United States, Italy and Netherlands. Howard Yeh's co-authors include James R. Berenson, Saroj Vadhan‐Raj, Susie Jun, Giorgio V. Scagliotti, Luís Costa, Roger von Moos, Penella J. Woll, Vânia Hungria, Vera Hirsh and Roger Dansey and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Howard Yeh

24 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

2011 877 citations David H. Henry, Luís Costa et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Howard Yeh United States	15	1.2k	526	443	363	311	24	1.7k
Allan Lipton United States	9	1000 0.8×	172 0.3×	113 0.3×	197 0.5×	434 1.4×	10	1.2k
John Hohneker United States	23	1.5k 1.2×	290 0.6×	124 0.3×	278 0.8×	171 0.5×	40	1.9k
Mimi I. Hu United States	31	1.6k 1.3×	558 1.1×	47 0.1×	592 1.6×	226 0.7×	117	3.3k
G. Gorzegno Italy	21	836 0.7×	249 0.5×	110 0.2×	99 0.3×	251 0.8×	51	1.4k
S Charhon France	16	702 0.6×	204 0.4×	160 0.4×	331 0.9×	119 0.4×	34	1.1k
Christian Rosenquist Denmark	13	496 0.4×	420 0.8×	126 0.3×	437 1.2×	50 0.2×	17	1.5k
J.J. Body Belgium	20	1.0k 0.8×	268 0.5×	32 0.1×	551 1.5×	372 1.2×	47	1.4k
J. Vinholes United Kingdom	16	2.1k 1.7×	251 0.5×	67 0.2×	246 0.7×	906 2.9×	37	2.6k
Marcello Tucci Italy	24	748 0.6×	403 0.8×	73 0.2×	76 0.2×	593 1.9×	100	1.9k
Robin K. Dore United States	14	662 0.5×	639 1.2×	85 0.2×	727 2.0×	52 0.2×	33	1.6k

Countries citing papers authored by Howard Yeh

Since Specialization

Citations

This map shows the geographic impact of Howard Yeh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Howard Yeh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Howard Yeh more than expected).

Fields of papers citing papers by Howard Yeh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Howard Yeh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Howard Yeh. The network helps show where Howard Yeh may publish in the future.

Co-authorship network of co-authors of Howard Yeh

This figure shows the co-authorship network connecting the top 25 collaborators of Howard Yeh. A scholar is included among the top collaborators of Howard Yeh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Howard Yeh. Howard Yeh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maio, Michele, Michael Schenker, Jacques Médioni, et al.. (2021). Phase 2 study of retifanlimab (INCMGA00012) in patients (pts) with selected solid tumors (POD1UM-203).. Journal of Clinical Oncology. 39(15_suppl). 2571–2571. 7 indexed citations

Plesner, Torben, Hendrik‐Tobias Arkenau, Peter Gimsing, et al.. (2015). Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503). Blood. 126(23). 507–507. 35 indexed citations

Plesner, Torben, Hendrik‐Tobias Arkenau, Henk M. Lokhorst, et al.. (2014). Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma.. Journal of Clinical Oncology. 32(15_suppl). 8533–8533. 32 indexed citations

Henry, David H., Saroj Vadhan‐Raj, Vera Hirsh, et al.. (2013). Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Supportive Care in Cancer. 22(3). 679–687. 130 indexed citations

Zuris, John A., et al.. (2012). NADPH Inhibits [2Fe-2S] Cluster Protein Transfer from Diabetes Drug Target MitoNEET to an Apo-acceptor Protein. Journal of Biological Chemistry. 287(15). 11649–11655. 26 indexed citations

Henry, David H., Luís Costa, François Goldwasser, et al.. (2011). Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma. Journal of Clinical Oncology. 29(9). 1125–1132. 877 indexed citations breakdown →

Hu, Mimi I., Rasim Gucalp, Karl Insogna, et al.. (2011). Denosumab for Treatment of Hypercalcemia of Malignancy in Patients with Solid Tumors or Hematological Malignancies Refractory to IV Bisphosphonates: A Single-Arm Multicenter Study. Blood. 118(21). 2483–2483. 4 indexed citations

Vij, Ravi, Noemi Horvath, Andrew Spencer, et al.. (2009). An open‐label, phase 2 trial of denosumab in the treatment of relapsed or plateau‐phase multiple myeloma. American Journal of Hematology. 84(10). 650–656. 72 indexed citations

Berenson, James R., Jeffrey Matous, Regina A. Swift, et al.. (2007). A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma. Clinical Cancer Research. 13(6). 1762–1768. 100 indexed citations

10.

Yeh, Howard & James R. Berenson. (2006). Myeloma bone disease and treatment options. European Journal of Cancer. 42(11). 1554–1563. 26 indexed citations

11.

Berenson, James R. & Howard Yeh. (2006). Arsenic Compounds in the Treatment of Multiple Myeloma: A New Role for a Historical Remedy. Clinical Lymphoma & Myeloma. 7(3). 192–198. 44 indexed citations

12.

Berenson, James R., Ralph V. Boccia, David S. Siegel, et al.. (2006). Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single‐arm study. British Journal of Haematology. 135(2). 174–183. 64 indexed citations

13.

Yeh, Howard, Haiming Chen, Regina A. Swift, et al.. (2006). Serum pleiotrophin levels are elevated in multiple myeloma patients and correlate with disease status. British Journal of Haematology. 133(5). 526–529. 13 indexed citations

14.

Yeh, Howard & James R. Berenson. (2006). Treatment for Myeloma Bone Disease. Clinical Cancer Research. 12(20). 6279s–6284s. 35 indexed citations

15.

Chen, Haiming, Richard A. Campbell, Cathy Wang, et al.. (2005). Transdifferentiation of Monocytes into Endothelial Cells by Pleiotrophin.. Blood. 106(11). 391–391. 3 indexed citations

16.

Berenson, James R., et al.. (2005). A Phase I/II Trial Evaluating the Combination of Arsenic Trioxide, Bortezomib and Ascorbic Acid for Patients with Relapsed or Refractory Multiple Myeloma.. Blood. 106(11). 2565–2565. 10 indexed citations

17.

Campbell, Richard A., Haiming Chen, Hee Jin Lee, et al.. (2005). Blocking Pleiotrophin Activity Inhibits Multiple Myeloma (MM) Cell Growth In Vitro and in a Severe Combined Immunodeficient (SCID)-hu Murine Model of Human MM.. Blood. 106(11). 114–114. 1 indexed citations

18.

Berenson, James R., Ralph V. Boccia, David S. Siegel, et al.. (2005). A Multicenter Phase II Study of Combination Treatment with Melphalan, Arsenic Trioxide and Vitamin C (MAC) for Patients with Relapsed or Refractory Multiple Myeloma.. Blood. 106(11). 2564–2564. 4 indexed citations

19.

Zhu, Ying, Michael A. Saunders, Howard Yeh, Wuguo Deng, & Kenneth K. Wu. (2002). Dynamic Regulation of Cyclooxygenase-2 Promoter Activity by Isoforms of CCAAT/Enhancer-binding Proteins. Journal of Biological Chemistry. 277(9). 6923–6928. 83 indexed citations

20.

Deng, Wuguo, Michael A. Saunders, Derek W. Gilroy, et al.. (2002). Purification and characterization of a cyclooxygenase‐2 and angiogenesis suppressing factor produced by human fibroblasts. The FASEB Journal. 16(10). 1286–1288. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact